Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
about
Genome-wide association studies: a primerPharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysisPharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesNo association of a set of candidate genes on haloperidol side effects.Pharmacogenetics of antipsychotics.Biomarkers in development of psychotropic drugs.WPA guidance on mental health and mental health care in migrants.Genomics for disease treatment and prevention.The promise and reality of pharmacogenetics in psychiatryPsychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.Ethics and neuropsychiatric genetics: a review of major issues.Clinical Predictors of Response to Clozapine in Patients with Treatment Resistant SchizophreniaFactors associated with response to clozapine in schizophrenia: a review.Dual eligibles with mental disorders and Medicare part D: how are they faring?The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration.Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Variability in the efficacy of psychopharmaceuticals: contributions from pharmacogenomics, ethnopsychopharmacology, and psychological and psychiatric anthropologies.Pharmacogenetics: a reality or misplaced optimism?Modelling and simulation of placebo effect: application to drug development in schizophrenia.Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine.A current snapshot of common genomic variants contribution in psychiatric disorders.New drug developments in psychosis: Challenges, opportunities and strategies.Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients.Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment?Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.New Targets for Schizophrenia Treatment beyond the Dopamine HypothesisAssociation of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD.Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans.Imaging genetics: implications for research on variable antidepressant drug response.A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes.A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.Psychiatric pharmacists' perception on the use of pharmacogenomic testing in the mental health population.General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment.
P2860
Q24273247-FA00A104-F9DF-43D2-9257-5BE111E7628EQ24600775-FFE2F22C-ECB4-43F2-8AE2-0C6FF95DBBD9Q28088705-27A7609E-9712-4B25-8DF6-C1A841D65BA8Q30424511-B480EA7B-A730-4E7D-9C92-51FD86DB4C75Q33836837-196F685D-9CFC-4581-9E69-AAAC9A0DA409Q33993209-1B0E55D3-C71D-46B6-8D44-AC5D21DD6A91Q34623395-AB811CC8-6681-410E-ABC7-1F0A9930E611Q34776933-B9FD18EE-BBA1-40CE-8E7E-A36546D55CA0Q35226451-8C817719-CAB3-4106-9FA7-66BCF4A21603Q35583046-5ACCD2DE-39E4-4DBA-9825-C8910D120F1BQ35985180-30194845-C9F4-40CC-A796-A94D55281E6EQ37299983-B6B91318-8E0F-42CA-BB30-2DD5C4B4D315Q37300007-3D030EE0-9EB0-45A4-A373-5B1AE8D03A02Q37412404-05E51FA0-C3A2-4938-A12F-0169FBDCA053Q37452489-D646AA40-FBEA-439B-B26E-90256CFC0EDFQ37612442-5342D797-6624-4A82-A735-287E8FB56EF6Q37952823-2016BA76-A2C9-495E-94C8-3A4E4B55D01AQ37960512-4E3C266C-A9B0-4190-8434-9494FB5054C6Q37979695-DEC2ACF1-90D2-4C9A-AE64-07A2AB11E4FDQ38003392-35D97527-00DC-4E77-8870-B96AA438D477Q38073697-18E41BC4-8C59-4E26-9F3A-2F1CE0AC912CQ38162870-F1A1C826-2D58-40BE-8F36-B49BAFB7EA73Q38916885-2BA87CC6-8879-4883-B925-3C5BE28D81A2Q38926246-EC508A85-F2AA-45FF-AC34-B50774C93C15Q39268347-2A1707B1-E3A8-4F63-BA1F-412C6DCF4826Q39369670-7C7A533D-D0D0-4200-A285-EFAA81781960Q39602459-095FE373-13BB-40CA-BB41-F7B3C75F6614Q41573540-6F34A547-B61C-48BF-B934-20752E7A8D00Q43053801-3F61D3C5-13FD-471B-8035-D8392406EB12Q44596771-99DFBB63-0328-4448-885F-0B2BB3D1BA96Q45754167-AB52E14D-3B4A-4431-8754-EC483958D09DQ45928687-E85CE9F8-A873-4EFE-841C-A119F78DF855Q48148747-0896A59D-3BE6-4ED0-90D7-487ED8C04522Q48262461-98832289-43C7-4C8A-8AEE-95074B4A95EAQ48639392-F7538168-2C47-4BC0-9B62-17B62B69644FQ48868283-BAEA0752-CE77-4D27-891A-649AA705DD6AQ50581598-02E8CC23-5A22-4863-90B2-FE992C43E6BFQ51509688-57CD91A8-C078-48FF-8045-02B4A894D98BQ51828618-04341B7D-F51D-428E-89F1-8F70E0E567DD
P2860
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@en
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@nl
type
label
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@en
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@nl
prefLabel
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@en
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@nl
P2860
P356
P1476
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
@en
P2093
Maria J Arranz
P2860
P304
P356
10.1093/SCHBUL/SBN114
P407
P50
P577
2008-08-27T00:00:00Z